Literature DB >> 24589194

Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel.

Todd J Anderson1, Jean Grégoire2, Robert A Hegele3, Patrick Couture4, G B John Mancini5, Ruth McPherson6, Gordon A Francis7, Paul Poirier8, David C Lau9, Steven Grover10, Jacques Genest10, André C Carpentier11, Robert Dufour12, Milan Gupta13, Richard Ward14, Lawrence A Leiter15, Eva Lonn16, Dominic S Ng17, Glen J Pearson18, Gillian M Yates19, James A Stone9, Ehud Ur5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24589194     DOI： 10.1016/j.cjca.2014.01.009

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  5 in total

1.  Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists.

Authors:  Ricky D Turgeon; Todd J Anderson; Jean Grégoire; Glen J Pearson
Journal:  Can Pharm J (Ott)       Date:  2015-01

2.  Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2014-05

3.  Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.

Authors:  Kentaro Sakamoto; Mitsunobu Kawamura; Takahide Kohro; Masao Omura; Takayuki Watanabe; Keiko Ashidate; Toshiyuki Horiuchi; Hidehiko Hara; Nobuo Sekine; Rina Chin; Motoyoshi Tsujino; Toru Hiyoshi; Motoki Tagami; Akira Tanaka; Yasumichi Mori; Takeshi Inazawa; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

4.  Comparing Guidelines for Statin Treatment in Canada and the United States.

Authors:  Deirdre A Hennessy; Tracey Bushnik; Douglas G Manuel; Todd J Anderson
Journal:  J Am Heart Assoc       Date:  2015-07-14       Impact factor: 5.501

5.  Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

Authors:  Helen M Colhoun; Jennifer G Robinson; Michel Farnier; Bertrand Cariou; Dirk Blom; Dean J Kereiakes; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari
Journal:  BMC Cardiovasc Disord       Date:  2014-09-20       Impact factor: 2.298
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.